Terumo Corporation, based in Japan, and the French company Diabeloop, have signed an agreement for a comprehensive strategic partnership. With this agreement, in addition to the current joint development of the AID system for Japan, they will work closely to bring Automated Insulin Delivery (AID) solutions to Europe with potential further global expansion.

The AID system is used for insulin-dependent diabetes management. It automates and personalizes the treatment of and contributes to reducing the heavy mental burden associated with the chronic condition. Hosted on a dedicated handset, the Diabeloop-developed self-learning algorithm is connected to a continuous glucose monitor (CGM) and an insulin pump. It analyzes the data in real time, and decides whether to maintain current insulin settings or adjust insulin delivery.  In Europe and the US, more and more people with diabetes are using or looking to use AID systems for better glucose control and improved quality of life. 

DBLG1, the state-of-the-art-algorithm solution of Diabeloop is currently available in several European markets.

In 2018, Terumo launched "MEDISAFE WITH", an insulin patch pump, that is designed to be wearable and lightweight for patient comfort and freedom. In addition, Terumo is the exclusive distributor of the Dexcom CGM system in Japan since 2019.

Since 2020, both companies have been working on the joint development of an AID system in Japan, with the aim of helping Japanese people with diabetes.